Coxibs, science, and the public trust

Comparative Study

Daniel H Solomon et al. Arch Intern Med. 2005.

. 2005 Jan 24;165(2):158-60.

doi: 10.1001/archinte.165.2.158.

No abstract available

Comment in

Inconsistency in the editorial process in Archives of Internal Medicine?
Bjarnason NH. Bjarnason NH. Arch Intern Med. 2005 Jun 27;165(12):1439-40; author reply 1440; discussion 1440. doi: 10.1001/archinte.165.12.1439-b. Arch Intern Med. 2005. PMID: 15983298 No abstract available.

The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG; Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators. Sowers JR, et al. Arch Intern Med. 2005 Jan 24;165(2):161-8. doi: 10.1001/archinte.165.2.161. Arch Intern Med. 2005. PMID: 15668361 Clinical Trial.
National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation.
Dai C, Stafford RS, Alexander GC. Dai C, et al. Arch Intern Med. 2005 Jan 24;165(2):171-7. doi: 10.1001/archinte.165.2.171. Arch Intern Med. 2005. PMID: 15668363
Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population.
Shaya FT, Blume SW, Blanchette CM, Weir MR, Mullins CD. Shaya FT, et al. Arch Intern Med. 2005 Jan 24;165(2):181-6. doi: 10.1001/archinte.165.2.181. Arch Intern Med. 2005. PMID: 15668364
Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors.
Battistella M, Mamdami MM, Juurlink DN, Rabeneck L, Laupacis A. Battistella M, et al. Arch Intern Med. 2005 Jan 24;165(2):189-92. doi: 10.1001/archinte.165.2.189. Arch Intern Med. 2005. PMID: 15668365